000 | 04006cam a2200625 a 4500 | ||
---|---|---|---|
001 | ocn666931928 | ||
003 | OCoLC | ||
005 | 20221128211200.0 | ||
006 | m d | ||
007 | cr cn||||||||| | ||
008 | 100929s2009 enka ob 001 0 eng d | ||
040 |
_aIDEBK _beng _epn _cIDEBK _dN$T _dEBLCP _dOCLCQ _dYDXCP _dOCLCQ _dMHW _dOCLCF _dUKDOC _dOCLCQ _dNLGGC _dOCLCQ _dD6H _dAGLDB _dZ5A _dOCLCQ _dVTS _dTOF _dAU@ _dJBG _dWYU _dSTF _dM8D _dOCLCO _dOCLCQ _dOCLCA _dOCLCQ _dUKAHL _dOCLCQ _dOCLCO |
||
019 |
_a416480892 _a815776118 _a965934893 |
||
020 |
_a9781846926013 _q(electronic bk.) |
||
020 |
_a1846926017 _q(electronic bk.) |
||
020 | _a1282093916 | ||
020 | _a9781282093911 | ||
020 | _a9781846920349 | ||
020 | _a1846920345 | ||
035 |
_a277322 _b(N$T) |
||
035 |
_a(OCoLC)666931928 _z(OCoLC)416480892 _z(OCoLC)815776118 _z(OCoLC)965934893 |
||
060 | 4 |
_aWD 200.5.H8 _bL762 2009 |
|
072 | 7 |
_aMED _x027000 _2bisacsh |
|
072 | 7 |
_aMED _x060000 _2bisacsh |
|
072 | 7 |
_aK _2bicssc |
|
049 | _aMAIN | ||
245 | 0 | 0 |
_aLipid disorders _c _h[E-Book] |
246 | 1 | 4 | _aTherapeutic strategies in lipid disorders |
260 |
_aOxford : _bClinical, _c2009. |
||
300 |
_a1 online resource (ix, 284 pages) : _billustrations |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
490 | 1 | _aTherapeutic strategies | |
504 | _aIncludes bibliographical references and index. | ||
520 | _aLipid disorders are now recognised as a diverse group of diseases that together represent one of the foremost risk factors for cardiovascular disease in general. Frequently present in association with other chronic illnesses such as hypertension, diabetes, and obesity, lipid disorders are a key therapeutic target for clinicians. This book examines the causes and consequences of lipid disorders, and the treatments available. Special chapters are dedicated to the associations between lipid disorders and other conditions, for example cerebrovascular disease and heart failure, as well as the wider. | ||
505 | 0 | _aEditorand Contributors; Foreword; Chapter 1: A global view of cardiovascular risk factors; Chapter 2: Low-density lipoprotein cholesterol as a therapeutic target; Chapter 3: High-density lipoprotein as a therapeutic target; Chapter 4: Apolipoprotein B in the therapy of atherogenic dyslipoproteinaemias; Chapter 5: Management of coronary heart disease patients; Chapter 6: Stroke and transient ischaemic attack prevention; Chapter 7: Diabetes and the metabolic syndrome; Chapter 8: Hypertension; Chapter 9: Treatment of familial hypercholesterolaemia. | |
505 | 8 | _aChapter 10: Lipid lowering in chronic kidney diseaseChapter 11: Statins and heart failure; Chapter 12: Absolute risk assessment in the general population; Chapter 13: Pleiotropic effects of statins and potential new indications; Chapter 14: The role of imaging endpoints in clinical trials; Chapter 15: Biomarkers in cardiovascular disease; Chapter 16: Novel lipid-modifying agents; Chapter 17: The enhanced evidence base and translation into improved outcomes; Abbreviations; Index. | |
590 | _aWorldCat record variable field(s) change: 650 | ||
650 | 0 |
_aLipids _xMetabolism _xDisorders. |
|
650 | 0 |
_aLipids _xMetabolism. |
|
650 | 2 |
_aDyslipidemias _xtherapy |
|
650 | 2 | _aLipid Metabolism | |
700 | 1 | _aTonkin, Andrew M. | |
830 | 0 | _aTherapeutic strategies. | |
856 | 4 | 0 |
_uhttps://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=277322 _yKingston Hospital NHS Foundation Trust OpenAthens account holders click here for access |
938 |
_a123Library _b123L _n1866 |
||
938 |
_aAskews and Holts Library Services _bASKH _nAH28329618 |
||
938 |
_aProQuest Ebook Central _bEBLB _nEBL434065 |
||
938 |
_aEBSCOhost _bEBSC _n277322 |
||
938 |
_aProQuest MyiLibrary Digital eBook Collection _bIDEB _n209391 |
||
938 |
_aYBP Library Services _bYANK _n3032031 |
||
942 | _n0 | ||
994 |
_a92 _bN$T |
||
999 |
_c89590 _d89590 |